JEFFREY E GERSHENWALD to Molecular Targeted Therapy
This is a "connection" page, showing publications JEFFREY E GERSHENWALD has written about Molecular Targeted Therapy.
Connection Strength
0.399
-
Lymphangiogenesis and hemangiogenesis: potential targets for therapy. J Surg Oncol. 2011 May 01; 103(6):489-500.
Score: 0.182
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
Score: 0.098
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.073
-
The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. J Transl Med. 2018 04 17; 16(1):101.
Score: 0.018
-
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
Score: 0.017
-
Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol. 2011 May 01; 103(6):538-49.
Score: 0.011